Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

Mosaic effectiveness: measuring the impact of novel PrEP methods.

Glidden DV, Mehrotra ML, Dunn DT, Geng EH.

Lancet HIV. 2019 Sep 27. pii: S2352-3018(19)30227-9. doi: 10.1016/S2352-3018(19)30227-9. [Epub ahead of print] Review.

PMID:
31570273
2.

Statistical approaches to accelerate the development of long-acting antiretrovirals for HIV pre-exposure prophylaxis.

Glidden DV.

Curr Opin HIV AIDS. 2019 Sep 24. doi: 10.1097/COH.0000000000000589. [Epub ahead of print]

PMID:
31567437
3.

Evaluating the impact of policies recommending PrEP to subpopulations of men and transgender women who have sex with men based on demographic and behavioral risk factors.

Janes H, Brown MD, Glidden DV, Mayer KH, Buchbinder SP, McMahan VM, Schechter M, Guanira J, Casapia M.

PLoS One. 2019 Sep 19;14(9):e0222183. doi: 10.1371/journal.pone.0222183. eCollection 2019.

4.

Advancing Novel PrEP Products - Alternatives to Non-Inferiority.

Glidden DV.

Stat Commun Infect Dis. 2019 Jan;11(1). pii: 20190011. doi: 10.1515/scid-2019-0011. Epub 2019 Aug 6.

5.

Correction: Retention and viral suppression in a cohort of HIV patients on antiretroviral therapy in Zambia: Regionally representative estimates using a multistage-sampling-based approach.

Sikazwe I, Eshun-Wilson I, Sikombe K, Czaicki N, Somwe P, Mody A, Simbeza S, Glidden DV, Chizema E, Mulenga LB, Padian N, Duncombe CJ, Bolton-Moore C, Beres LK, Holmes CB, Geng E.

PLoS Med. 2019 Aug 30;16(8):e1002918. doi: 10.1371/journal.pmed.1002918. eCollection 2019 Aug.

6.

The Connection between the Averted Infections Ratio and the Rate Ratio in Active-control Trials of Pre-exposure Prophylaxis Agents.

Dunn DT, Glidden DV.

Stat Commun Infect Dis. 2019 Jan;11(1):20190006. doi: 10.1515/scid-2019-0006. Epub 2019 Jul 12.

7.

Baseline Characteristics Explain Differences in Effectiveness of Randomization to Daily Oral TDF/FTC PrEP Between Transgender Women and Cisgender Men Who Have Sex With Men in the iPrEx Trial.

Mehrotra ML, Westreich D, McMahan VM, Glymour MM, Geng E, Grant RM, Glidden DV.

J Acquir Immune Defic Syndr. 2019 Jul 1;81(3):e94-e98. doi: 10.1097/QAI.0000000000002037. No abstract available.

PMID:
31192894
8.

Exercise Improves Self-Reported Sexual Function Among Physically Active Adults.

Fergus KB, Gaither TW, Baradaran N, Glidden DV, Cohen AJ, Breyer BN.

J Sex Med. 2019 Aug;16(8):1236-1245. doi: 10.1016/j.jsxm.2019.04.020. Epub 2019 May 31.

9.

Retention and viral suppression in a cohort of HIV patients on antiretroviral therapy in Zambia: Regionally representative estimates using a multistage-sampling-based approach.

Sikazwe I, Eshun-Wilson I, Sikombe K, Czaicki N, Somwe P, Mody A, Simbeza S, Glidden DV, Chizema E, Mulenga LB, Padian N, Duncombe CJ, Bolton-Moore C, Beres LK, Holmes CB, Geng E.

PLoS Med. 2019 May 31;16(5):e1002811. doi: 10.1371/journal.pmed.1002811. eCollection 2019 May. Erratum in: PLoS Med. 2019 Aug 30;16(8):e1002918.

10.

Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project.

Spinelli MA, Glidden DV, Anderson PL, Gandhi M, McMahan VM, Defechereux P, Schechter M, Veloso VG, Chariyalertsak S, Guanira JV, Bekker LG, Buchbinder SP, Grant RM.

AIDS Res Hum Retroviruses. 2019 Sep;35(9):788-793. doi: 10.1089/AID.2018.0297. Epub 2019 Jun 19.

PMID:
31119944
11.

Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing.

Spinelli MA, Glidden DV, Anderson PL, Gandhi M, Cohen S, Vittinghoff E, Coleman ME, Scott H, Bacon O, Elion R, Kolber MA, Buchbinder SP, Liu AY.

J Acquir Immune Defic Syndr. 2019 Jun 1;81(2):158-162. doi: 10.1097/QAI.0000000000002005.

PMID:
31095005
12.

Differentiated Care Preferences of Stable Patients on Antiretroviral Therapy in Zambia: A Discrete Choice Experiment.

Eshun-Wilson I, Mukumbwa-Mwenechanya M, Kim HY, Zannolini A, Mwamba CP, Dowdy D, Kalunkumya E, Lumpa M, Beres LK, Roy M, Sharma A, Topp SM, Glidden DV, Padian N, Ehrenkranz P, Sikazwe I, Holmes CB, Bolton-Moore C, Geng EH.

J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):540-546. doi: 10.1097/QAI.0000000000002070.

13.

Brief Report: Cocaine Use and Pre-exposure Prophylaxis: Adherence, Care Engagement, and Kidney Function.

Hojilla JC, Satre DD, Glidden DV, McMahan VM, Gandhi M, Defechereux P, Guanira JV, Mehrotra M, Grant RM, Carrico AW.

J Acquir Immune Defic Syndr. 2019 May 1;81(1):78-82. doi: 10.1097/QAI.0000000000001972.

PMID:
30730359
14.

Low tenofovir level in urine by a novel immunoassay is associated with seroconversion in a preexposure prophylaxis demonstration project.

Spinelli MA, Glidden DV, Rodrigues WC, Wang G, Vincent M, Okochi H, Kuncze K, Mehrotra M, Defechereux P, Buchbinder SP, Grant RM, Gandhi M.

AIDS. 2019 Apr 1;33(5):867-872. doi: 10.1097/QAD.0000000000002135.

PMID:
30649051
15.

Strengthening HIV-prevention trials: a dose of implementation science?

Geng EH, Glidden DV, Padian N.

Lancet Infect Dis. 2018 Nov;18(11):1166-1168. doi: 10.1016/S1473-3099(18)30567-X. Epub 2018 Oct 24. No abstract available.

PMID:
30507394
16.

Risk Factors for Recurrent Acute Kidney Injury in a Large Population-Based Cohort.

Liu KD, Yang J, Tan TC, Glidden DV, Zheng S, Pravoverov L, Hsu CY, Go AS.

Am J Kidney Dis. 2019 Feb;73(2):163-173. doi: 10.1053/j.ajkd.2018.08.008. Epub 2018 Oct 25.

PMID:
30482577
17.

The averted infections ratio: a novel measure of effectiveness of experimental HIV pre-exposure prophylaxis agents.

Dunn DT, Glidden DV, Stirrup OT, McCormack S.

Lancet HIV. 2018 Jun;5(6):e329-e334. doi: 10.1016/S2352-3018(18)30045-6. Review.

18.

Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals.

Jotwani V, Scherzer R, Glidden DV, Mehrotra M, Defechereux P, Liu A, Gandhi M, Bennett M, Coca SG, Parikh CR, Grant RM, Shlipak MG.

J Acquir Immune Defic Syndr. 2018 Jun 1;78(2):169-174. doi: 10.1097/QAI.0000000000001654.

19.

The Role of Social Relationships in PrEP Uptake and Use Among Transgender Women and Men Who Have Sex with Men.

Mehrotra ML, Rivet Amico K, McMahan V, Glidden DV, Defechereux P, Guanira JV, Grant RM.

AIDS Behav. 2018 Nov;22(11):3673-3680. doi: 10.1007/s10461-018-2151-0.

PMID:
29754268
20.

Application of a Multistate Model to Evaluate Visit Burden and Patient Stability to Improve Sustainability of Human Immunodeficiency Virus Treatment in Zambia.

Roy M, Holmes C, Sikazwe I, Savory T, Mwanza MW, Bolton Moore C, Mulenga K, Czaicki N, Glidden DV, Padian N, Geng E.

Clin Infect Dis. 2018 Sep 28;67(8):1269-1277. doi: 10.1093/cid/ciy285.

21.

Skating on thin ice: stimulant use and sub-optimal adherence to HIV pre-exposure prophylaxis.

Hojilla JC, Vlahov D, Glidden DV, Amico KR, Mehrotra M, Hance R, Grant RM, Carrico AW.

J Int AIDS Soc. 2018 Mar;21(3):e25103. doi: 10.1002/jia2.25103.

22.

Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine.

Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM.

Clin Infect Dis. 2018 Jul 18;67(3):411-419. doi: 10.1093/cid/ciy083.

23.

Estimated mortality on HIV treatment among active patients and patients lost to follow-up in 4 provinces of Zambia: Findings from a multistage sampling-based survey.

Holmes CB, Sikazwe I, Sikombe K, Eshun-Wilson I, Czaicki N, Beres LK, Mukamba N, Simbeza S, Bolton Moore C, Hantuba C, Mwaba P, Phiri C, Padian N, Glidden DV, Geng E.

PLoS Med. 2018 Jan 12;15(1):e1002489. doi: 10.1371/journal.pmed.1002489. eCollection 2018 Jan.

24.

HIV sero disclosure among men who have sex with men and transgender women on HIV pre-exposure prophylaxis.

Hojilla JC, Mehrotra M, Truong HM, Glidden DV, Amico KR, McMahan V, Vlahov D, Chariyalertsak S, Guanira JV, Grant RM, For The iPrEx Study Team.

AIDS Care. 2018 Apr;30(4):466-472. doi: 10.1080/09540121.2017.1394437. Epub 2017 Oct 28.

25.

HIV prevention trial design in an era of effective pre-exposure prophylaxis.

Cutrell A, Donnell D, Dunn DT, Glidden DV, Grobler A, Hanscom B, Stancil BS, Meyer RD, Wang R, Cuffe RL.

HIV Clin Trials. 2017 Nov-Dec;18(5-6):177-188. doi: 10.1080/15284336.2017.1379676. Epub 2017 Oct 17. Review.

26.

Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.

Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM.

J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):177-182. doi: 10.1097/QAI.0000000000001475.

27.

Response to: A double-edged sword: does highly active antiretroviral therapy contribute to syphilis incidence by impairing immunity to Treponema pallidum?

Glidden DV, Mayer K, Grant RM.

Sex Transm Infect. 2017 Aug;93(5):313. doi: 10.1136/sextrans-2017-053212. Epub 2017 Apr 13. No abstract available.

28.

Association Between a Virtual Glucose Management Service and Glycemic Control in Hospitalized Adult Patients: An Observational Study.

Rushakoff RJ, Sullivan MM, MacMaster HW, Shah AD, Rajkomar A, Glidden DV, Kohn MA.

Ann Intern Med. 2017 May 2;166(9):621-627. doi: 10.7326/M16-1413. Epub 2017 Mar 28.

PMID:
28346946
29.

The Causal Effect of Tracing by Peer Health Workers on Return to Clinic Among Patients Who Were Lost to Follow-up From Antiretroviral Therapy in Eastern Africa: A "Natural Experiment" Arising From Surveillance of Lost Patients.

Bershetyn A, Odeny TA, Lyamuya R, Nakiwogga-Muwanga A, Diero L, Bwana M, Braitstein P, Somi G, Kambugu A, Bukusi E, Hartogensis W, Glidden DV, Wools-Kaloustian K, Yiannoutsos C, Martin J, Geng EH; East Africa International Epidemiologic Databases to Evaluate AIDS (EA-IeDEA) Consortium.

Clin Infect Dis. 2017 Jun 1;64(11):1547-1554. doi: 10.1093/cid/cix191. Erratum in: Clin Infect Dis. 2017 Oct 15;65(8):1431-1433.

30.

Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations.

Koss CA, Bacchetti P, Hillier SL, Livant E, Horng H, Mgodi N, Mirembe BG, Gomez Feliciano K, Horn S, Liu AY, Glidden DV, Grant RM, Benet LZ, Louie A, van der Straten A, Chirenje ZM, Marrazzo JM, Gandhi M.

AIDS Res Hum Retroviruses. 2017 Aug;33(8):778-783. doi: 10.1089/aid.2016.0202. Epub 2017 Mar 2.

31.

Limitations of using the Lorenz curve framework to understand the distribution of population viral load: authors' reply.

Christopoulos KA, Hartogensis W, Glidden DV, Pilcher CD, Gandhi M, Geng EH.

AIDS. 2017 Mar 13;31(5):742-743. doi: 10.1097/QAD.0000000000001407. No abstract available.

32.

Incorporation of the time aspect into the liability-threshold model for case-control-family data.

Cederkvist L, Holst KK, Andersen KK, Glidden DV, Frederiksen K, Kjaer SK, Scheike TH.

Stat Med. 2017 May 10;36(10):1599-1618. doi: 10.1002/sim.7229. Epub 2017 Jan 23.

PMID:
28114748
33.

Strict blood pressure control associates with decreased mortality risk by APOL1 genotype.

Ku E, Lipkowitz MS, Appel LJ, Parsa A, Gassman J, Glidden DV, Smogorzewski M, Hsu CY.

Kidney Int. 2017 Feb;91(2):443-450. doi: 10.1016/j.kint.2016.09.033. Epub 2016 Dec 4.

34.

The Lorenz curve: a novel method for understanding viral load distribution at the population level.

Christopoulos KA, Hartogensis W, Glidden DV, Pilcher CD, Gandhi M, Geng EH.

AIDS. 2017 Jan 14;31(2):309-310. doi: 10.1097/QAD.0000000000001336.

35.

Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study.

Gandhi M, Glidden DV, Mayer K, Schechter M, Buchbinder S, Grinsztejn B, Hosek S, Casapia M, Guanira J, Bekker LG, Louie A, Horng H, Benet LZ, Liu A, Grant RM.

Lancet HIV. 2016 Nov;3(11):e521-e528. doi: 10.1016/S2352-3018(16)30153-9. Epub 2016 Aug 31.

36.

Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.

Castillo-Mancilla J, Seifert S, Campbell K, Coleman S, McAllister K, Zheng JH, Gardner EM, Liu A, Glidden DV, Grant R, Hosek S, Wilson CM, Bushman LR, MaWhinney S, Anderson PL.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6692-6697. doi: 10.1128/AAC.01017-16. Print 2016 Nov.

37.

Pharmacology supports on-demand PrEP.

Glidden DV, Anderson PL, Grant RM.

Lancet HIV. 2016 Sep;3(9):e405-e406. doi: 10.1016/S2352-3018(16)30114-X. No abstract available.

38.

BP Control and Long-Term Risk of ESRD and Mortality.

Ku E, Gassman J, Appel LJ, Smogorzewski M, Sarnak MJ, Glidden DV, Bakris G, GutiƩrrez OM, Hebert LA, Ix JH, Lea J, Lipkowitz MS, Norris K, Ploth D, Pogue VA, Rostand SG, Siew ED, Sika M, Tisher CC, Toto R, Wright JT Jr, Wyatt C, Hsu CY.

J Am Soc Nephrol. 2017 Feb;28(2):671-677. doi: 10.1681/ASN.2016030326. Epub 2016 Aug 11.

39.

Impact of genetic variants on the upstream efficacy of renin-angiotensin system inhibitors for the prevention of atrial fibrillation.

Roberts JD, Dewland TA, Glidden DV, Hoffmann TJ, Arking DE, Chen LY, Psaty BM, Olgin JE, Alonso A, Heckbert SR, Marcus GM.

Am Heart J. 2016 May;175:9-17. doi: 10.1016/j.ahj.2016.02.002. Epub 2016 Feb 13.

40.

PrEP adherence among trans women in Brazil-access needed for this key population - Authors' reply.

Sevelius J, Deutsch MB, Glidden DV, Grant RM.

Lancet HIV. 2016 May;3(5):e200-1. doi: 10.1016/S2352-3018(16)30023-6. No abstract available.

41.

The Effect of Depressive Symptoms on Adherence to Daily Oral PrEP in Men who have Sex with Men and Transgender Women: A Marginal Structural Model Analysis of The iPrEx OLE Study.

Mehrotra ML, Glidden DV, McMahan V, Amico KR, Hosek S, Defechereux P, Mayer KH, Veloso VG, Bekker LG, Avelino-Silva VI, Schechter M, Grant RM.

AIDS Behav. 2016 Jul;20(7):1527-34. doi: 10.1007/s10461-016-1415-9.

42.

HIV moments and pre-exposure prophylaxis.

Grant RM, Glidden DV.

Lancet. 2016 Apr 9;387(10027):1507-1508. doi: 10.1016/S0140-6736(16)30125-8. Epub 2016 Apr 7. No abstract available.

43.

Contemporary Profile of Seizures in Neonates: A Prospective Cohort Study.

Glass HC, Shellhaas RA, Wusthoff CJ, Chang T, Abend NS, Chu CJ, Cilio MR, Glidden DV, Bonifacio SL, Massey S, Tsuchida TN, Silverstein FS, Soul JS; Neonatal Seizure Registry Study Group.

J Pediatr. 2016 Jul;174:98-103.e1. doi: 10.1016/j.jpeds.2016.03.035. Epub 2016 Apr 19.

44.

Height at First RRT and Mortality in Children.

Ku E, Fine RN, Hsu CY, McCulloch C, Glidden DV, Grimes B, Johansen KL.

Clin J Am Soc Nephrol. 2016 May 6;11(5):832-9. doi: 10.2215/CJN.08250815. Epub 2016 Mar 1.

45.

Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension.

Glidden DV, Amico KR, Liu AY, Hosek SG, Anderson PL, Buchbinder SP, McMahan V, Mayer KH, David B, Schechter M, Grinsztejn B, Guanira J, Grant RM.

Clin Infect Dis. 2016 May 1;62(9):1172-7. doi: 10.1093/cid/ciw022. Epub 2016 Jan 20.

46.

Patient-reported factors associated with reengagement among HIV-infected patients disengaged from care in East Africa.

Camlin CS, Neilands TB, Odeny TA, Lyamuya R, Nakiwogga-Muwanga A, Diero L, Bwana M, Braitstein P, Somi G, Kambugu A, Bukusi EA, Glidden DV, Wools-Kaloustian KK, Wenger M, Geng EH; East Africa International Epidemiologic Databases to Evaluate AIDS (EA-IeDEA) Consortium.

AIDS. 2016 Jan 28;30(3):495-502. doi: 10.1097/QAD.0000000000000931.

47.

Crude incidence in two-phase designs in the presence of competing risks.

Rebora P, Antolini L, Glidden DV, Valsecchi MG.

BMC Med Res Methodol. 2016 Jan 11;16:5. doi: 10.1186/s12874-015-0103-1.

48.

Retention in Care and Patient-Reported Reasons for Undocumented Transfer or Stopping Care Among HIV-Infected Patients on Antiretroviral Therapy in Eastern Africa: Application of a Sampling-Based Approach.

Geng EH, Odeny TA, Lyamuya R, Nakiwogga-Muwanga A, Diero L, Bwana M, Braitstein P, Somi G, Kambugu A, Bukusi E, Wenger M, Neilands TB, Glidden DV, Wools-Kaloustian K, Yiannoutsos C, Martin J.

Clin Infect Dis. 2016 Apr 1;62(7):935-944. doi: 10.1093/cid/civ1004. Epub 2015 Dec 17.

49.

Association of Frailty based on self-reported physical function with directly measured kidney function and mortality.

Delgado C, Grimes BA, Glidden DV, Shlipak M, Sarnak MJ, Johansen KL.

BMC Nephrol. 2015 Dec 9;16:203. doi: 10.1186/s12882-015-0202-6.

50.

HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.

Deutsch MB, Glidden DV, Sevelius J, Keatley J, McMahan V, Guanira J, Kallas EG, Chariyalertsak S, Grant RM; iPrEx investigators.

Lancet HIV. 2015 Dec;2(12):e512-9. doi: 10.1016/S2352-3018(15)00206-4. Epub 2015 Nov 6.

Supplemental Content

Loading ...
Support Center